Navigation Links
Keith McCormick Joins Trovagene, Inc. as Head of Commercial Operations
Date:4/23/2012

SAN DIEGO, April 23, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets:  TROV.PK), a developer of transrenal molecular diagnostics, announced the appointment of Keith McCormick as head of commercial operations, effective April 16, 2012.

McCormick brings extensive pharmaceutical and diagnostic sales, marketing and operational experience. Most recently, he served as senior director of sales operations at bioTheranostics, Inc.  McCormick served as a member of the AviaraDx, Inc. executive team, where he built the commercial sales and marketing organization that successfully launched CancerTYPE ID, a molecular cancer classifier, as well as the Breast Cancer Index, a prognostic test for women with ER-positive, lymph-node negative breast cancer.  In September 2008, AviaraDx was sold to bioMerieux S.A. of France and renamed bioTheranostics.

Prior to AviaraDx, McCormick spent 10 years at Schering Plough and Biogen Idec, selling and marketing specialty pharmaceuticals. His career included assignments and leadership roles in sales, sales management, market research, product management, and new product planning.  McCormick began his healthcare career with Dianon Systems, a diagnostic specialty laboratory providing serum, tissue and genetic tests for cancer and inherited disorders.

"Keith's broad experience and in-depth understanding of the oncology and diagnostic markets will guide our commercial efforts," said Antonius Schuh, Ph.D., chief executive officer for Trovagene. "The company will focus its internal efforts on urine-based laboratory-developed tests for the detection of oncogene mutations in cancer patients. Keith's access to top-tier cancer centers and clinical opinion leaders, and his proven track record in building commercial organizations, will be critical components of Trovagene's success."

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is developing its patented technology for the detection of transrenal DNA and RNA, short nucleic acid fragments, originating from normal and diseased cell death that cross the kidney barrier and can be detected in urine.

Trovagene has a dominant patent position as it relates to transrenal molecular testing. It has U.S. and European patent applications and issued patents that cover testing for HPV and other infectious diseases, cancer, transplantation, prenatal and genetic testing. In addition, it owns worldwide rights to nucleophosmin-1 (NPM1), an informative biomarker for acute myeloid leukemia (AML) and mutations in the SF3B1 gene, which have been shown to be associated with chemotherapy response in CLL (chronic lymphocytic leukemia) patients.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2011 and other periodic reports filed with the Securities and Exchange Commission.

Contact:     

 Stephen Zaniboni 


 858-496-7466


 szaniboni@trovagene.com


'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Soligenix Announces Appointment of Jerome Zeldis, MD, PhD and Keith Brownlie, CPA to its Board of Directors
2. Samsung Medison America Welcomes Brian Keith as Sales General Manager, USA
3. Cardiogenesis Executive Chairman Paul J. McCormick Updates Commercial and Regulatory Progress in Interview With Wall Street Reporter, Available Online
4. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
5. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
6. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
7. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
8. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
9. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
10. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
11. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
Breaking Medicine Technology:
(Date:12/2/2016)... , ... December 02, 2016 , ... "Pro3rd Accents Volume ... editors to create versatile lower third titles with just a few clicks of the ... Volume 2 includes 30 lower third animations. Choose from various styles with accented animations, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... to needy individuals and families from eight different sites throughout Miami-Dade and Broward ... Over 1,000 volunteers worked very hard on Thanksgiving morning by putting together individual ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... Laboratory Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health radio ...
(Date:11/30/2016)... Massachusetts (PRWEB) , ... November 30, 2016 , ... ... proud to announce that we have been designated as a Cigna Infertility Center ... or exceed rigorous performance standards. , “It’s an honor to be designated ...
(Date:11/30/2016)... ... 30, 2016 , ... "I hate when the mixture of saliva and toothpaste ... an inventor from Bridgewater, N.J. "I thought that there had to be a way ... developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush ...
Breaking Medicine News(10 mins):